You are here

Alzheimer's disease

Eisai is building a bespoke Cambridge research center with a $100M-plus plan to find new ways to tackle Alzheimer’s

Eisai is building a bespoke Cambridge research center with a $100M-plus plan to find new ways to tackle Alzheimer’s

Endpoints

Alzheimer's disease

Flag link:

Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done

Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done

CP Wire

Alzheimer's disease

BACE inhibitors

Flag link:

Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done

Alzheimer's disease

Flag link:

Cognition Therapeutics Receives $6.6M from NIA to Study Elayta Synaptoprotective Mechanism of Action in Alzheimer's

Cognition Therapeutics Receives $6.6M from NIA to Study Elayta Synaptoprotective Mechanism of Action in Alzheimer's

CP Wire

Cognition Therapeutics

Alzheimer's disease

Flag link:

Alzheimer’s Disease: Companies Weigh Revised FDA Draft Guidance

Alzheimer’s Disease: Companies Weigh Revised FDA Draft Guidance

RAPS.org

Alzheimer's disease

Denali Therapeutics

Flag link:

Cognition Therapeutics Receives $6.6M from NIA to Study Elayta Synaptoprotective Mechanism of Action in Alzheimer's

Cognition Therapeutics

Alzheimer's disease

Flag link:

Janssen drops the BACE as Alzheimer’s candidate joins fail list

Janssen drops the BACE as Alzheimer’s candidate joins fail list

Fierce Biotech

BACE inhibitors

Alzheimer's disease

Flag link:

EIP Pharma Receives $20.5 Million Series B to Fund Alzheimer's Candidate

EIP Pharma Receives $20.5 Million Series B to Fund Alzheimer's Candidate

CP Wire

Alzheimer's disease

Flag link:

EIP Pharma Receives $20.5 Million Series B to Fund Alzheimer's Candidate

Alzheimer's disease

Flag link:

Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s

Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s

Endpoints

Alzheimer's disease

Flag link:

Australian and US Scientists Discover New Insights into Dementia and Alzheimer’s

Australian and US Scientists Discover New Insights into Dementia and Alzheimer’s

CP Wire

Alzheimer's disease

drug development

Flag link:

Australian and US Scientists Discover New Insights into Dementia and Alzheimer’s

Alzheimer's disease

Flag link:

Merck study may signal doom for a broad group of pivotal Alzheimer’s studies

Merck study may signal doom for a broad group of pivotal Alzheimer’s studies

Endpoints

Alzheimer's disease

Flag link:

Biogen Pays $50 million to Reduce Future Royalty Payments on Alzheimer’s Drug Aducanumab

Biogen Pays $50 million to Reduce Future Royalty Payments on Alzheimer’s Drug Aducanumab

CP Wire

Alzheimer's disease

Flag link:

Biogen Pays $50 million to Reduce Future Royalty Payments on Alzheimer’s Drug Aducanumab

Alzheimer's disease

Flag link:

Alzheon steps back from an IPO, further than ever from a PhIII Alzheimer’s study

Alzheon steps back from an IPO, further than ever from a PhIII Alzheimer’s study

Endpoints

Alzheimer's disease

clinical trials

Flag link:

Anticholinergic drugs may induce dementia

Anticholinergic drugs may induce dementia

GoinPharma

Alzheimer's disease

anticholinergics

Flag link:

After yet another PhIII Alzheimer’s failure, experts try to map a path out of the wrecking field

After yet another PhIII Alzheimer’s failure, experts try to map a path out of the wrecking field

Endpoints

Alzheimer's disease

Flag link:

vTv therapeutics Alzheimer's Drug Fails to Reach Primary Endpoints in Ph III study

vTv therapeutics Alzheimer's Drug Fails to Reach Primary Endpoints in Ph III study

CP Wire

vTv Therapeutics

Alzheimer's disease

Flag link:

vTv therapeutics Alzheimer's Drug Fails to Reach Primary Endpoints in Ph III study

vTv Therapeutics

Alzheimer's disease

Flag link:

Pages